In the current study, we have developed a magnetic resonance imaging (MRI)-based method for noninvasive detection of complement activation in placenta and fetal brain in vivo in utero. Using this method, we found that anti-complement C3-targeted ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles bind within the inflamed placenta and fetal brain cortical tissue, causing a shortening of the T2* relaxation time. We used two mouse models of pregnancy complications: a mouse model of obstetrics antiphospholipid syndrome (APS) and a mouse model of preterm birth (PTB). We found that detection of C3 deposition in the placenta in the APS model was associated with placental insufficiency characterised by increased oxidative stress, decreased vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) levels and intrauterine growth restriction. We also found that fetal brain C3 deposition was associated with cortical axonal cytoarchitecture disruption and increased neurodegeneration in the mouse model of APS and in the PTB model. In the APS-model, fetuses that showed increased C3 in their brains additionally expressed anxiety-related behaviour after birth. Importantly, USPIO did not affect pregnancy outcomes and liver function in the mother and the offspring , suggesting that this method may be useful for detecting complement activation in vivo in utero and predicting placental insufficiency and abnormal fetal neurodevelopment that leads to neuropsychiatric disorders.
INTRODUCTION
Identification of new biomarkers to predict bad pregnancy/fetal outcomes would be of enormous clinical benefit. In particular, a non-invasive detection of a biomarker that can identify pregnancies at risk would allow determining optimal timing of delivery and implementation of neuroprotective strategies to the mother. Currently, there are very few methods to predict adverse pregnancy/fetal outcomes.
Bad pregnancy outcomes have been associated with the activation of inflammatory pathways (1) , in particular the complement system (2, 3) . Pregnancy complications such as antiphospholipid antibody (aPL)-induced placental pathology and fetal growth restriction and preterm birth has been associated with complement activation (4) (5) (6) (7) . Complement activation has also been related to abnormal development of the fetal brain cortex in premature birth in mice (8) . In addition, a spectrum of brain abnormalities and cognitive impairment has been described in infants born to mothers affected by APS (9) (10) (11) .
During complement activation, C3 activation fragments (C3b/iC3b/C3d) are covalently attached to the injured tissue. Ultrasmall superparamagnetic iron oxide (USPIO, diameter:5-40 nm) particles shorten the T2-and T2* relaxation time and are therefore used as negative contrast agents in magnetic resonance imaging (MRI) (12) Moreover, by conjugating USPIOs to vectors that bind specific molecules, the USPIO can be used to detect those molecular targets in vivo. In the current study, we used USPIO nanoparticles conjugated to antibodies to C3 activation products as contrast agent of MR imaging to determine the presence of complement activation/inflammation in the placenta and fetal brain to predict pregnancy/fetal outcomes.
MATERIAL AND METHODS

Animals
All housing and experimental procedures were performed in compliance with the UK Home Office Animals Scientific Procedures Act 1986 (Home Office project licence number 60/4305). C57BL/6 mice (2-3 months old) purchased from commercial vendors were used in all experiments. Females were mated with previously isolated males. The presence of a vaginal plug defined day 0 of pregnancy
Mouse model of preterm birth (PTB model)
On day 15 of pregnancy, mice received intravaginal LPS to induce preterm birth (4, 8) . Mice were scanned in the morning of day 16. Scanned mice showed signs of preterm labor (vaginal bleeding and increased expression of connexin 43 -marker of myometrial contractility-in myometrial biopsies postmortem). An age-matched group was studied as control. Mice were sacrificed after imaging, the fetuses were weighed and the fetal brains were harvested for immunohistochemical studies.
Mouse model of obstetric APS (APS model)
On days 8 and 12 of pregnancy, mice were treated with intraperitoneal injections of mouse antiphospholipid (aPL) monoclonal antibodies (FB1, 1mg). The control group received mouse IgG (IP, 1mg). Mouse monoclonal aPL antibodies FB1 (IgG2bκ) -with anticardiolipin specificities and complement binding capacity (13) -were obtained from NZW x BXSB F1 mice and generously provided by M. Monestier (Temple University School of Medicine, Philadelphia, PA) (13).
On day 15 the mice were subjected to MRI studies and killed after imaging. Placentas and fetal brains were collected for immunohistochemical and biochemical studies.
Placentas from the APS-group and respective control group were analysed for oxidative stress levels and vascular endothelial growth factor VEGF content. Isoprostane 8-isoprostaglandin F2a (STAT-8) was measured as a marker for oxidative stress. Placental tissue was homogenized in 9 volumes of 0.1 M Tris (pH 7.4) containing 1 mM EDTA and 10 μM indomethacin and stored at −80°C in the presence of butylated hydroxytoluene (5mg/100 ml) before being assayed for free 8-isoprostane using a STAT-8-Isoprostane EIA kit (Cayman Chemical, Ann Arbor, MI). For VEGF content measurements placentas were homogenised in 9 volumes of 0.1 M Tris (pH 7.4). Placental VEGF levels were measured by ELISA (R&D Systems, Inc, Minneapolis, MN, USA). PlGF was measured by immunohistochemistry using a specific antibody anti PlGF (Novus Niological)
A group of control and APS pregnant mice were allowed to give birth and behavioural studies were performed in the male offspring.
Behavioural tests
Behavioural tests were performed in 2 male pups/mother 60 days after birth (PND60). Elevated Plus-Maze and open-field tests were used to measure anxiety levels. In the openfield test, time spent in the centre and number of entries to the center were recorded. In the elevated plus-maze, time spent in open arm and number of entries to the open arm were calculated. Behavioural tests were not performed in the PTB-model because the pups did not survive due to immaturity (day 16).
Magnetic Resonance Imaging Studies
Conjugation of antiC3-antibodies with nanoparticules and test for C3 binding -Nanomag-D-SPIO 20 nm nanoparticles (surface COOH) and MACS separator with MS columns were purchased from Micromod (Miltenyi Biotech GmbH, Germany). USPIO (ultrasmall superparamagnetic iron oxide particles) were conjugated to monoclonal antibodies (rat IgG1) that bind specific complement activation C3 fragments C3b, iC3b, C3c deposited on tissue ( clone 2/11 provided by John D Lambris, University of Pennsylvania, PA, USA) (14) . The conjugation was performed following an established protocol that uses N-ethyl-N-(3-dimethyl aminopropyl) carbodiimide hydrochloride and N-hydroxy succinimide (NHS) (15) . Rat IgG1, isotype control antibody, was also conjugated to nanoparticles following the same protocol. The unconjugated antibodies were separated from conjugated antibodies by MACS column. The final products of conjugation were suspensions without precipitate. The amount of iron conjugated was determined by potassium thiocyanate method using FeCl3-6H2O as a reference.
The presence of anti-C3 antibodies or isotype control antibodies on the surface of conjugated USPIO was confirmed by measuring protein content by Bradford method and the amount of antibody in all preparations was 32-40 μg/mg nanoparticles. The functionality/ binding of USPIO conjugated anti-C3 antibodies was confirmed by immunohistochemistry. MRL/lpr mice develop lupus nephritis with deposition of C3 activation fragments in kidney (16) . Kidney frozen sections from MRL/lpr mice (16) and C3-/-mice (negative control) were incubated with USPIO-conjugated anti-C3 antibody (dilution 1:100) and unconjugated anti-C3 antibody (dil 1:100). A secondary antibody FITC-conjugated (Santa Cruz Biotechnology, Inc., dilution 1:400) was used to develop the immunohistochemical reaction.
MR Imaging protocols-Animals from the APS and PTB model groups and respective controls (mIgG-treated mice and untreated age-matched controls) received the USPIO particles (0.5 mg/mouse) (unconjugated, conjugated with anti-C3 antibody and conjugated with rat IgG1) intravenously (volume less than 100μl) as a bolus (administration time, 2-3 seconds) 12-14 hours before the imaging session. After the imaging sessions, mice were sacrificed and placentas and fetal brains isolated for immunohistochemical and biochemical studies.
MR Imaging Protocols-All MRI experiments were performed using a 7 Tesla horizontal bore NMR spectrometer (Agilent Technologies, Yarnton, UK), equipped with a high-performance gradient insert (60 mm inner diameter), maximum gradient strength 1000 mT/m. The mice were anesthetized with 1.8 % isofluorane in oxygen/air (50/50, 1 L/min) and placed in a cradle (Rapid Biomedical GmbH, Rimpar, Germany). The rectal temperature and respiration rate were monitored throughout the experiments, and body temperature was maintained at 37 °C with a heat fan. A 33-mm diameter birdcage volume coil (Rapid Biomedical GmbH, Rimpar, Germany) was used for radio frequency transmission and signal reception. For anatomical assessment, respiration-gated T2-weighted fast spin echo images (echo train length of 8) of 1 mm slice thickness in a sagittal orientation were collected with the following parameters: repetition time (TR) ≈ 3000 ms depending on the respiration rate; effective echo time = 48 ms; 24 MR Imaging Data Analysis-All images were processed and T2* maps generated with VnmrJ software (Version 3.2A, Agilent Technologies). For each T2* map, regions of interest (ROI) were drawn in each organ of interest making sure to stay well within the boundaries of the respective organ and the mean ROI T2* values were used as quantitative measures of T2* relaxation times (ms) for each tissue type.
Immunohistochemical studies (IHC)-Fetal brains were harvested in the APS and PTB models and respective controls and incubated overnight in PFA 4% with 10% sucrose for cytoprotection. Fetal brain tissue was then frozen in O.C.T. compound, and cut into 10 μm sections. Immunohistochemical studies were performed to evaluate the expression of microtubule associated protein-2 (MAP-2; Sigma-Aldrich dilution 1/100) -a marker of intact neuronal cell bodies-and neurofilament 200 (NF-200; Sigma Aldrich, dilution 1/400) -to evaluate dendritic and axons structure. Neurodegeneration was measured using FluoroJade B (Millipore, Millerica, MA, USA), a polyanionic fluorescein derivative which sensitively and specifically binds to degenerating neurons (17) . 10 views per slide were analyzed in each experimental condition.
Mice from the PTB and APS groups, and respective controls that did not receive USPIO injections were killed after MR imaging and placentas and fetal brains were processed for immunohistochemistry. Frozen sections were stained for complement deposition, using monoclonal anti C3b, iC3b, C3c antibodies (clone 2/11 provided by John D Lambris, University of Pennsylvania, Philadelphia) (14) .
To study if USPIO-anti-C3 antibodies cross the placenta and the fetal blood brain barrier immunohistochemical studies were performed. FITC-conjugated antibodies to rat IgG1 were used to visualize the presence of USPIO-antiC3 antibodies in placentas and fetal brains in APS and PTB-mice after the MRI studies.
Immunohistochemical studies to detect the presence of aPL antibody FB1 were also performed in placentas and fetal brains from APS-mice. Placental growth factor was determined by immunohistochemistry in frozen sections from placentas in APS and mouseIgG-treated mice. Confocal double-labelled microphotographs were captured using a Leica SP5 spectral confocal microscope with settings appropriate to the fluorophores present.
Isolation of fetal cortical neurons
Cortical neurons from day 16 fetuses were isolated as previously described (8, 18) and cultured on coverslips coated with laminin/polylysin (5 × 10 5 cell/cm 2 ). Control cells extend their neurites and establish synapses in culture after 10 days in culture and thus represent an accessible model to study cortical brain development (18) . After 7 days in culture (7DIV) neurons were exposed to aPL antibody FB1 or control antibody (mouse IgG). Formation of neuritic networks in each experimental group was evaluated on 10DIV by immunohistochemistry using βIII tubulin antibodies after fixation with paraformaldehyde 4%.
Effects of USPIOs on pregnancy
To study the potential effects of USPIOs in pregnancy, fetal and placental weight at day 16 was recorded in control and USPIO-treated mice after MRI imaging. Placental vascular endothelial growth factor (VEGF) and isoprostane 8-isoprostaglandin F2a 8-STAT content were measured by ELISA as described above. Another group of control and USPIO-treated mice were allowed to give birth time of delivery was recorded. To investigate clearance of USPIO nanoparticles in these groups, T2* maps for the liver were generated. Liver function tests were performed by measuring hepatic enzymes alanine transaminase (ALT) and aspartate transaminase (AST) with commercial kits (Abcam) in the mother during and after pregnancy and in the offspring.
Statistical analysis
Data are expressed as mean ± SD. Statistical differences between groups were determined using one-way ANOVA with subsequent two-tailed Student t test.
RESULTS
Conjugation of USPIOs to anti-C3 antibodies does not affect antibody binding capacity
After conjugation, the reactivity of anti-C3 antibodies was verified by immunohistochemistry. USPIO-conjugated antiC3 antibodies were used to detect C3 deposition in glomeruli from MRL/lpr mice (Fig 1Ai) and compared to unlabbeled antiC3 antibody (Fig 1Aii) . Using USPIO-conjugated antiC3 antibodies as primary antibodies and FITC-conjugated secondary antibodies, C3 deposition was detected in the kidneys from MRL/lpr mice. USPIO-conjugated antiC3 antibodies detect C3 (Fig 1Ai) in a similar manner to unconjugated antiC3 antibodies (Fig 1Aii) indicating that the binding capacity of the antibody is preserved. In addition, USPIO-conjugated antiC3 antibodies did not bind to kidneys from C3 deficient mice (Fig 1Bi) that do not express C3 , as shown by immunohistochemistry using unconjugated antiC3 (Fig 1Bii) , indicating that the binding of USPIO-conjugated anti-C3 antibodies to C3 is specific.
USPIO-conjugated anti C3 antibodies cross the placenta and the fetal blood brain barrier
Immunohistochemical studies performed after the MRI studies showed the presence of USPIO-conjugated anti C3 antibodies in the placenta of APS mice (Fig 1C) and in the fetal brain of APS (Fig 1D) and PTB mice injected with USPIO-antiC3 (Fig 1E) compared to their respective controls (mIgG-treated mice and age-matched controls). These data demonstrate that antiC3 antibodies conjugated to USPIO cross the placenta and the fetal blood brain barrier. Within the fetal brain and placenta, most of the USPIO-conjugated antiC3 antibodies were found in the cortex and the labyrinth respectively.
Injection of USPIO-conjugated antiC3 caused a significant reduction in T2*-relaxation time in fetal brains in PTB and APS-mice indicating increased C3 deposition
We previously demonstrated abnormal cortical cytoarchitecture and increased neurodegeneration in fetal brain in the mouse model of PTB (8) . Cortical fetal brain abnormalities were associated with increased complement split product C5a levels. Interestingly, here we found increased C3 deposition in the fetal cortical brain in PTB-mice (Fig 2A) compared to age-matched control. A significant reduction in T2* time -indicative of positive binding of USPIO-conjugated antiC3-was observed in vivo in the fetal brains in utero in PTB mice compared to age-matched control and PTB mice that received USPIOs or control Ab-USPIOs (Fig 2B) . Macrophages, present in inflamed tissue, may phagocyte USPIOs and thus cause a T2* signal diminution. T2* time in placentas in APS and fetal brains in APS and PTB mice injected with USPIOs was not different from USPIO-treated control mice, indicating that phagocytic cells do not play a significant role in the decreased T2* times observed in APS and PTB mice treated with USPIO-conjugated anti-C3 treated antibodies. Thus, the MRI data suggests that the T2* signal diminution in APS and PTB mice is due to the presence of C3. T2* maps are shown in Figure 2C . As previously described diminished NF-200 and MAP-2 staining was also observed in the cortex of fetal brains in PTB-mice compared to age-matched control (Fig 2A) , indicative of a disruption of cortical dendritic and axonal cytoarchitecture. In addition increased neurodegeneration, measured by FluoroJade B, was also observed in the fetal cortical brain in PTB-mice compared to age-matched control (Fig 2A) .
A similar association between complement deposition and abnormal cortical fetal brain development was observed in the APS model. First, we demonstrated that aPL antibodies FB1 are able to cross the blood brain barrier and reach the fetal brain. Indeed, FB1 antibodies were found in fetal brain cortex by immunohistochemistry (Fig 3A) . T2* values in APS-mice that received USPIO-antiC3 were lower than APS-mice that received only USPIO or mouse IgG-treated mice that received USPIO-antiC3 (Fig 3B) . This suggests that complement C3 deposition is observed in fetal brains in the APS model. Immunohistochemical studies confirmed the presence of C3 deposition in the fetal brain cortex in APS-mice (Fig 3C) . Like in the PTB, increased C3 deposition and abnormal cortical brain development were observed in the brains of fetuses exposed to aPL in utero. The diminished NF200 and MAP-2 staining observed in the fetal brains in APS compared to mouse-IgG treated mice suggest an abnormal cortical neurons development (Fig 3D) . In addition, increased neurodegeneration was observed in fetal brains from APS-mothers ( Fig  3D) .
Neurotoxic effects of aPL antibodies
To confirm the detrimental effects of aPL on the developing fetal brain we studied isolated cortical neurons from day 16 fetuses. Immunohistochemical procedures determined that most cultured cells (>95%) express βIII tubulin (Fig 4A) , protein associated with cortical neurons and not found in glial cells. These cells extend their neurites and establish synapses becoming mature neurons after 10 days in culture. To study the effects of aPL on developing neurons in vitro we exposed the cells on day 7 (7 DIV) to FB1 antibody. The neuronal culture media includes fetal calf serum as a source of complement. As a quantitative measure of neuronal injury during neuronal development, we analyzed the growth of projections emanated from the neuronal cell bodies. At day 10, long axons were observed in cultured control cortical neurons (incubated with mouse IgG) (162±32μm) while the length of axons in aPL-exposed neurons was considerably reduced after the addition of aPL to the media on 7 DIV (39±11μm) (Fig 4A) . Incubation of cortical neurons with aPL in the absence of complement C3 (C3-/-serum) prevented aPL-induced neurotoxic effects. Long axons were observed in cultured cortical neurons incubated with FB1 plus C3 deficient serum., suggesting a role for complement in aPL-induced neurotoxicity
Behavioural abnormalities in the offspring in the APS model
The open field test and the elevated plus maze test showed increased anxiety-related behaviour in the offspring from APS-mice (Fig 4B and 4C) . Offspring from APS-mothers show a significant decrease in the percentage of time spent in the center and a significant reduction in the number of entries into the center in the open field test (Fig 4B) when compared to control group and mice born to mouse IgG-treated mothers) consistent with anxiety-related behaviour. In the elevated plus maze, offspring from APS mothers showed a significant decrease in the number of times they explore the open arms and the time spent in the open arms was also less when compared to mice born form control and mIgG-treated mothers (Fig 4C) . Locomotor activity did not change among groups.
Decreased T2*-relaxation time in placentas from APS mice that received antiC3-USPIO
Complement activation and placental inflammation are crucial events in obstetric APS (19) . Decreased T2* time was observed in placentas from APS-mice that received USPIO-antiC3 antibodies compared to APS-mice treated with USPIOs alone and control mouse IgG-treated mice injected with USPIO-antiC3 (Fig 5A) . The fast pin echo MRI coronal view (Fig 5B) clearly shows a placenta in APS-mice. Increased C3 deposition in placentas from APS-mice was also detected by immunohistochemistry (Fig 5C) . Abundant C3 deposition was observed in the labyrinth, crucial placental structure responsible for gas and nutrient exchange between the mother and the fetus. Increased C3 deposition in placentas from APSmice was associated with increased oxidative stress -measured as STAT-8 content -( Fig  5D) and decreased levels of VEGF ( Fig 5E) and PlGF (Fig 5F) . In addition, intrauterine growth restriction and decreased placental weight was observed in fetuses from APS-mice compared to control mice treated with mouse IgG (Fig 5G) .
USPIO administration did not affect liver function and pregnancy outcomes
It has been described that administration of silica and titanium dioxide nanoparticles (0.8 mg/mouse, nanoparticle diameter: 35 and 70 nm) causes pregnancy complications (20) . In the present study, mice treated with USPIO nanoparticles (0.5 mg/mouse, diameter: 20 nm) had normal pregnancy outcomes. USPIO-treated mice gave birth at term like control groups (pregnancy length (days): USPIO (n=4): 20.2±0.8 vs control (n=6): 20.6±0.5)). In addition, fetal and placental weights at day 16 in USPIO-treated mice were not different from control (Fig 6A) . Oxidative stress levels (STAT-8 levels) and VEGF concentration in placentas from USPIO-treated mice were not different from control mice (Fig 6B and 6C) . T2* values in placentas from control untreated-mice were similar to USPIO-treated mice (T2* (ms): control (n=6): 10.2±4.3 vs USPIO (n=4):9.1±5.7), suggesting that USPIO nanoparticles do not accumulate in the placenta. Interestingly, a lower T2* value was found in the maternal liver of USPIO-treated mice when compared to control (T2* (ms): control (n=6): 13.7±2.2 vs USPIO (n=4):4.4±2.6*, *p<0.01), suggesting that USPIOs are cleared by the liver. Measurement of hepatic enzymes AST and ALT activity, showed that USPIOs do not affect liver function. AST and ALT activity during pregnancy and after pregnancy in USPIOtreated mice were not different from control females (Fig 6D) 
DISCUSSION
Preterm birth (PTB) is a major public health problem (21) . More than 15 million babies are born prematurely worldwide. When babies are born before they are fully developed, they face many serious medical problems, such as neurodevelopmental impairment (22) .
Unfortunately, in the majority of the cases of PTB, there are few tests that can be employed to predict if a fetus is at risk for the development of brain injury. In the antiphospholipid syndrome (APS), fetuses exposed to aPL antibodies in utero are also at risk. In APS, miscarriage, fetal death and placental pathologies are common (19, 23, 24) . There is growing evidence about the transplacental passage of aPL antibodies and a spectrum of brain abnormalities and cognitive impairment has been described in infants born to mothers affected by APS (9-11), suggesting that exposure to aPL in utero affects fetal brain development and thus might induce behavioural and cognitive problems later on in life. In our studies, we showed that during pregnancy, complement activating aPL antibody FB1 crosses the placenta and the blood brain barrier (BBB) reaching the fetal brain and affecting its normal development. This is in agreement with the literature that shows that maternal antibodies have direct access to the developing brain during gestation (25) .
Inflammation, in particular complement activation, is a common mediator in the pathogenesis of preterm birth and obstetric APS (2, 4, 5, 7, 26) . In this study, using nanotechnology, we successfully developed a non invasive in utero method to determine the presence of complement activation/inflammation in the placenta and fetal brain to predict pregnancy/fetal outcomes in preterm birth and pregnancies complicated with APS.
Ultrasmall superparamagnetic iron (USPIO) oxide particles are magnetic resonance contrast agents that give rise to a significant shortening of T2-and T2*relaxation time (12) . USPIOs can be conjugated to vectors directed to specific targets and detected by magnetic resonance imaging in vivo. In this study we conjugated USPIOs to monoclonal antibodies to complement C3 split products (C3b, iC3b, C3c) to detect complement activation in vivo in utero by MRI. Importantly, we were able to show that USPIO-conjugated anti-C3 antibodies cross the placenta and the fetal blood brain barrier reaching the fetal brain. That IgG antibodies cross the placenta and the fetal blood brain barrier is in accordance with other studies (27, 28) . In addition, the BBB is developing during gestation allowing antibodies to have direct access to the brain during gestation (29) .
Injection of USPIO-conjugated antiC3 caused a significant reduction in T2*-relaxation time -indicative of increased C3 deposition-in placentas and fetal brains from abnormal pregnancies. Increased C3 deposition in placenta and fetal brains was associated with abnormal cortical fetal brain development and placental abnormalities in pregnancies compromised by PTB and APS. In the APS model increased C3 deposition in placenta was associated with placental insufficiency characterised by increased oxidative stress, decreased levels of proangiogenic factor VEGF and PlGF and decreased placental and fetal weight. This suggests that measuring C3 deposition using USPIOs and MRI during pregnancy might be a useful method to predict placental pathologies, intrauterine growth restriction and fetal brain abnormalities.
Generally, T2-relaxation time diminishes when blood flow is diminished and oxyhemoglobin levels are low. Considering the increased oxidative stress observed in placentas in APS-mice, we expected to see a diminished T2 signal in untreated APS-mice compared to control mice. While T2* signal values in placentas from APS mice were slightly lower than in mice treated with control antibody they did not reach statistical significance. This data suggests that placental blood flow is not significantly compromised in APS.
C3 deposition in fetal brain was associated with cytoarchitectural cortical neurons abnormalities in PTB and APS-mice. We previously demonstrated that complement activation plays a detrimental role in cortical brain development in preterm fetuses and in vitro using cultured isolated fetal cortical neurons (8) . Here, we also showed that the neurotoxic effects of aPL on neuritic network formation in vitro is also dependent on complement activation. The role of complement in brain injury remains controversial and most of the previously published studies were performed in adult animals. In favour of the deleterious effects of complement in fetal brain injury, a study showed that C3 is depleted in the blood of neonates who subsequently develop cerebral palsy (30) . In addition complement depletion has shown to improve cerebral blood flow and neurological function after ischaemia in adult rats (31) and reduced post ischemic cerebral infarct volume and atrophy in neonatal rats (32) . Other studies showed that complement inhibition failed to prevent brain injury caused by thromboembolic stroke (33) and hypoxia-ischemia (34) in adult animals. A recent study showed that hypoxic/ischaemic (HI) injury in neonates is ameliorated in mice that overexpress C3a (35) . However in this study, HI injury was induced at postnatal day 9 and only white matter injury was evaluated. Our studies demonstrate an association between increased fetal brain C3 deposition and abnormal cortical fetal brain development in day 16 fetuses in utero. Interestingly, we were able to correlate cortical brain abnormal development with behavioral changes in the APS mice. Increased anxiety was observed in the offspring of APS-mice, suggesting that in utero exposure to aPL antibodies causes abnormal cortical development and suggests that C3 might be a footprint for adverse fetal outcomes. Our studies associating abnormal fetal cortical development with increased anxiety in the offspring of APS-mice are in agreement with the literature that shows that during, prefrontal cortex brain injury, the neural networks involved in the regulation of anxiety are compromised (36) . Interestingly, it has been described that adult mice with APS showed a pattern of moving along the edges of the open field rather than randomly through the center (37) . A similar behavior, was observed in the offspring of APS-mothers in our studies.
While C3 deposition in fetal brains and placentas in APS can be simply explained by the activation of the classical pathways by aPL antibodies (5, 26) , the cause of C3 activation in fetal brains in PTB is not fully understood. We previously proposed that C5a generated in the cervix during preterm labor can reach the utero and the fetal brain. We can speculate that C5a-generated during spontaneous preterm labor-could activate neurons to release reactive oxygen species which further cleave C3 creating a complement activation feedback cycle.
It was previously demonstrated that placental complement deposition is associated with adverse pregnancy outcomes in APS in humans and mice (19) . Interestingly, complement deposition in human placentas in APS was found in the villous tree, vascular bed site for feto-maternal exchange, equivalent to the labyrinth in mice (19) . Here we show that increased placental complement deposition is predictive of placental insufficiency resulting in intrauterine growth restriction in APS.
A recent study also demonstrated the usefulness of superparamagnetic iron oxide (SPIO) -conjugated nanoparticles to detect complement activation in vivo (38) . In this study the authors successfully showed complement deposition in glomerulonephritis in mice by using SPIO particles conjugated to human complement receptor 2 (CR2) (38) .
In conclusion, using this in utero non invasive method we found that complement activation is a footprint for cortical fetal brain abnormalities and behavioural changes in pregnancy complicated by APS and of abnormal neuronal cytoarchitecture in cortical brain in PTB. In addition, increased complement deposition in placentas predicted placental abnormalities and intrauterine growth restriction in the mouse model of APS. Contrary to a previous publication, showing that nanoparticles cause pregnancy complications (17) , our data show that USPIO administration to pregnant mice is safe and no placental/fetal abnormalities are observed. The MRI studies show that the USPO nanoparticles used in this study -of smaller size than the ones used in the previous study-are rapidly cleared through the liver. Normal liver function was observed in USPIO-treated mothers (during pregnancy and after pregnancy) and in their offspring when compared to control animals, emphasizing that USPIO are not hepatotoxic. That USPIOs did not affect pregnancy outcomes, suggests that this non invasive in utero method to detect complement activation using anti-complement antibodies conjugated to USPIOs might be safe to use in humans and might help predict bad pregnancy/fetal outcomes in pregnancies at risk. The identification of fetuses with neurodevelopmental and/or placental abnormalities during pregnancy would allow the possibility of giving the mother neuroprotective strategies to modulate inflammation and prevent abnormal fetal autcomes A-Fetal and placental weight at day 16 in USPIO-treated mice were not different from control untreated mice. n=4-5 mice/group. B-Oxidative stress levels (STAT-8 levels) in placentas from USPIO-treated mice were not different from control mice. n=4-5 mice/group. C-VEGF levels in placentas from USPIO-treated mice were not different from control mice. n=4-5 mice/group. D-Hepatic enzymes (ALT and AST) activity in serum in mothers (during pregnancy -day 14) and post partum (21 days) and offspring in USPIO-treated and control mice
